|
|
Дата |
---|
04.08.2025 |
01.08.2025 |
31.07.2025 |
30.07.2025 |
29.07.2025 |
28.07.2025 |
25.07.2025 |
24.07.2025 |
23.07.2025 |
22.07.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.01
|
1.12
|
1.07
|
1.01
|
1.09
|
1.01
|
|
|
2 169.03
|
15.00
|
0.77
|
1.15
|
1.07
|
1.03
|
1.07
|
1.05
|
|
|
1 652.86
|
24.00
|
1.02
|
1.14
|
1.04
|
1.04
|
1.13
|
1.08
|
|
|
3 022.63
|
24.00
|
1.00
|
1.12
|
1.06
|
1.0455
|
1.065
|
1.0455
|
|
|
5 483.80
|
8.00
|
1.02
|
1.05
|
1.05
|
1.05
|
1.07
|
1.05
|
|
|
6 474.50
|
12.00
|
0.9964
|
1.16
|
1.01
|
1.00
|
1.105
|
1.07
|
|
|
10 258.33
|
49.00
|
1.02
|
1.14
|
1.11
|
1.05
|
1.11
|
1.06
|
|
|
6 353.36
|
18.00
|
1.07
|
1.17
|
1.065
|
1.06
|
1.14
|
1.105
|
|
|
8 062.76
|
36.00
|
1.04
|
1.08
|
0.91
|
0.91
|
1.095
|
1.08
|
|
|
6 222.71
|
49.00
|
0.8605
|
0.96
|
0.87
|
0.8465
|
0.9199
|
0.9199
|
|
|
2 279.30
|
19.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть